Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment

BACKGROUND: We report a subgroup analysis of afatinib with respect to its efficacy, safety, and the long‐term survival of patients in a Named Patient Use program at a single institution. METHODS: We analyzed 60 patients with stage IV non‐small cell lung cancer (NSCLC) who had been treated with ≥1 li...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hayoung, Lee, Jae‐Kyeong, Oh, Hyung‐Joo, Kim, Min‐Seok, Kho, Bo Gun, Park, Cheol Kyu, Oh, In‐Jae, Kim, Young‐Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107028/
https://www.ncbi.nlm.nih.gov/pubmed/33811467
http://dx.doi.org/10.1111/1759-7714.13957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107028/
https://www.ncbi.nlm.nih.gov/pubmed/33811467
http://dx.doi.org/10.1111/1759-7714.13957

Ejemplares similares